Between 1987 and 1988 our research group made a couple of interesting findings. First, we discovered that vascular endothelial cells are able to generate nitric oxide gas (NO)1, thus explaining the actions of the 'endothelium-derived relaxing factor' that had been described some seven years earlier2. And subsequently we found that NO was synthesized directly from the aminoacid L-arginine3. Here I present an overview of the new understanding that NO has brought to physiology and pathophysiology, with particular emphasis on the therapeutic possibilities that have arisen as a consequence.
We started to call the biochemical pathway the Larginine:NO pathway, and the enzyme responsible for this conversion NO synthase3. To demonstrate the formation of NO from L-arginine we cultured vascular endothelial cells on microcarrier beads and perfused them in vitro with two types of arginine, either uniformly labelled, i.e. with 15N-labelled nitrogen in all the nitrogen atoms of the molecule, or guanidino labelled, i.e. labelled in two guanidino nitrogen atoms. The effluent was connected directly to a mass spectrometer and we measured the formation of 15N-labelled NO. Every time we stimulated the cells with bradykinin, we could see the release of 15N-labelled NO and, since the amounts that were generated from both types of arginine were very similar, we concluded that NO was specifically made from the guanidino nitrogen atoms of the aminoacid4. Shortly after this it was discovered that, in the process of making NO, molecular oxygen was introduced in the formation of N-hydroxy L-arginine, which is an intermediate in the synthesis and later on in the formation of L-citrulline, which is the co-product of the generation of NO. The NO produced in this way is usually transferred from a generator cell to an effector cell where it exerts a biological function. In the case of the vasculature, it goes from the endothelial to the smooth muscle cell to activate the soluble guanylate cyclase and by doing so it produces vascular relaxation5.
We also identified an inhibitor of the synthesis of NO. ingested9. These were significant observations because L-NMMA, unlike noradrenaline or angiotensin, is devoid of any vasoconstrictor activity in the vasculature. L-NMMA produces vasoconstriction in vivo by taking away a normal physiological NO-dependent vasodilator tone, significant in the control and regulation of blood flow and blood pressure. So we proposed that there is an active vasodilator system in the vasculature, represented by the generation of NO, which is constantly opposed by vasoconstrictor influences in the vessel wall. These experiments have been repeated in many different laboratories around the world and probably the most important recent development in this area is that mutant mice, in which the gene that encodes eNOS has been deleted, have been shown to have higher blood pressure than the wild type controls10. We have recently carried out some studies in these eNOS knockout animals and have found that, while in wild-type (control) mice the difference in blood pressure between female and male animals is not significant, in the eNOS knock-out animals the males have a much greater increase in blood pressure than the females (Rees DD, Monkhouse JE, Davies N, Huang P, and Moncada S, unpublished) ( Figure 1 ). Such animals will be very important from now on for identification of the phenotype which represents the lack of NO synthase in the vasculature. Since NO is also an inhibitor of platelet aggregation and vascular smooth muscle cell proliferation, playing a general homoeostatic regulatory role in the vessel wall, studies in these animals will throw light on the relevance of NO not only in relation to the homoeostatic functioning of the vascular wall but also in relation to its response to injury.
Before the discovery of NO, the general view was that hypertension was most often due to excessive vasoconstrictor activity in the vasculature. However, our studies indicated that a lack of vasodilator tone might have exactly the same result. We if we gave L-NMMA to inhibit production of NO, the resultant vasoconstriction was greater in the normotensive controls than in the hypertensives. Thus we have identified an animal model of hypertension in which there is clearly a decrease in production of NO. This animal model also has lower sodium excretion than the normotensive controls. Since NO is involved in the excretion of sodium in the kidney we have suggested that a decrease in production of NO might lead to two accompanying defects namely, an increase in vascular reactivity and a decrease in sodium excretion.
In addition to its vasodilator actions, NO We are used to thinking of neurotransmitters as being synthesized in vesicles, stored there and released during nerve stimulation, after which they specifically activate certain receptors. Nitric oxide, however, seems to be synthesized on demand-Le. after nerve stimulation-with an action that spreads over a wide region; from a single point release in the brain, NO might influence a network of neurons over a distance of 100 ,um. If this is the case then probably NO should be regarded more as a coordinator of neuronal function than as a simple neurotransmitter.
We now know that a large network of nerves in the periphery, which were classified when discovered about 25 years ago as non-adrenergic and non-cholinergic, can all be termed as nitrergic because they release NO19-21. These nerves are widely distributed in the blood vessels of the brain, in the airways and the pulmonary circulation, in the gastrointestinal tract and in the genitourinary tract. In the mammalian stomach NO produces the adaptive relaxation that occurs when the volume of the contents increases. Throughout the gastrointestinal system, especially in the sphincters, the nitrergic nerves produce a relaxant tone. In rats, administration of an NO synthase inhibitor has been shown to increase both intraluminal pressure and phasic movements22. So NO released by nitrergic nerves maintains a dilator tone throughout the gastrointestinal system. We looked at the possibility that there might be a human disease related to a decrease in NO generated by nNOS. We investigated the disease achalasia, in which there is a closure of the gastro-oesophageal sphincter, comparing biopsies of achalasia patients with those from patients who were to be operated on for other reasons. We found that in the patients with achalasia there was no immunostaining for NO synthase, while in the myenteric plexuses of patients who did not have achalasia there was clear staining for the enzyme23. At around the time we published this paper, there was a report also suggesting that children with pyloric stenosis had subnormal NO production in the area of the pyloric sphincter. Interestingly, if you 'knock out' the gene that encodes the nNOS, these mutant animals show a syndrome similar to hypertrophy of the pyloric sphincter24.
The L-arginine: NO pathway seems to be a primitive system that has developed along with the animal kingdom. There is now evidence that NO has very similar roles in primitive species to those it has in mammals. We have studied the relaxation of the stomach of the starfish. The stomach has a pyloric part and a cardiac part, and the animal everts its stomach in order to pick up food from the bottom of the ocean. Using an antibody that we had developed to identify mammalian nNOS, we found immunostaining of neurons and fibres in the starfish stomach25. Since the starfish is a primitive species, these observations indicate that the function of NO has been highly conserved throughout evolution. Another area in which nitrergic nerves play a role is the genitourinary tract. Penile erection in animals and human beings is totally dependent on the generation of NO by nerves that innervate structures in the corpus cavernosum. We have recently completed a study of immunostaining with a specific antibody for nNOS (Rodrigo J, Cellek S, Roile M, Martinez-Murillo R, Bentura M, Fernandez A, Serrano J, Martinez-Valasco J, Alonso D, Santacana M, Uttenthal L, Moncada S, unpublished). We found staining for nNOS around the blood vessels in the corpus cavernosum. There is evidence that the dysfunction of the gut and of penile erection that occurs in diabetes could be due to specific damage of the nitrergic innervation in these organs.
IMMUNOLOGY AND INFLAMMATION
The third isoform of NO synthase (iNOS) was originally identified in macrophages26. Circulating macrophages that are not activated do not produce NO, but if they are activated with certain cytokines or with lipopolysaccharide there is de novo induction of NO synthase, which generates NO in large quantities and for very long periods. This differs from eNOS and nNOS which release small quantities of NO in response to receptor stimulation. This iNOS in inflammatory cells uses NO as a cytostatic and cytotoxic agent27'28. Nitric oxide inhibits enzymes in the mitochondria, especially complex I and complex IV, as well as enzymes in the nucleus such as ribonucleotide reductase, responsible for the synthesis of DNA. Nitric oxide released by iNOS from murine macrophages is cytostatic and cytotoxic for protozoan parasites, fungal cells and bacteria. It has been shown that human macrophages can kill Leishmania major by the production of NO. Thus NO, either on its own or in combination with oxygen radicals, might be a more important cytotoxic or cytostatic agent than oxygen radicals themselves. We have found that topical application of an NO donor, S-nitrosopenicillamine, in patients with cutaneous leishmaniasis kills the parasites and heals the lesion29 (Figure 2 forms of human and animal inflammation, NO is produced in large quantities and is probably an important mediator of the acute and chronic signs of inflammation. This has led to the idea that selective inhibitors of iNOS may in the future be useful in the treatment of inflammatory conditions. One of the most interesting aspects of the biology of NO is the way in which it changes from being a physiological mediator to a cytostatic/cytotoxic agent. One possible mechanism is that NO interacts with superoxide, which is also generated in inflammatory conditions, to form peroxynitrite. This compound is a highly oxidant species that will produce tissue damage. We have been investigating this phenomenon in mitochondria and have found that NO selectively and at physiological concentrations reversibly inhibits the last enzyme in the respiratory cycle, cytochrome c oxidase (complex IV). In this way NO plays an important role as a regulator of cell respiration. If, however, NO is produced in large quantities for long periods it will inhibit cytochrome c oxidase in a way in which oxygen will not be able to displace it from the enzyme. In such a situation, superoxide may be generated in the mitochondria itself and interact with NO to form peroxynitrite, which we know will block complex I and complex III irreversibly. So from inhibition of complex IV, which might be a physiological way in which NO can regulate respiration, NO could have adverse effects through the irreversible inhibition of complex 132.
In conclusion, NO is a ubiquitous molecule that not only has many different physiological functions, some of which remain to be unravelled, but also provides an immunological defence mechanism with implications for pathophysiology. Twelve years ago we were not even aware that NO was produced by the body; today we see it as a mediator with a very wide range of biological activities. Undoubtedly, understanding of the actions of NO will lead to new forms of therapy for human disease.
